About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

COMPLETEDPhase 1

Study of Single-Ascending Doses of DS-6016a in Healthy Japanese Subjects

Single-Ascending Dose Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of DS-6016a After Subcutaneous Injection in Healthy Japanese Subjects

NCT04818398•Daiichi Sankyo Co., Ltd.

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Fibrodysplasia Ossificans Progressiva

Interventions

DS-6016a

Placebo

Locations

1

Japan

Locations (1)

Medical Corporation Heishinkai OPHAC Hospital

Osaka, Japan

Key Dates

Start Date

April 1, 2021

Primary Completion Date

December 24, 2021

Completion Date

July 26, 2022

Last Updated

August 3, 2022

Related Studies

RECRUITINGPhase 2

Saracatinib Trial TO Prevent FOP

NCT04307953

Fibrodysplasia Ossificans Progressiva

Active Not RecruitingPhase 3

A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)

NCT05394116

Fibrodysplasia Ossificans Progressiva

Active Not RecruitingPhase 2/3

A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

NCT06508021

Fibrodysplasia Ossificans Progressiva

COMPLETEDPhase 3

A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.

NCT05027802

Fibrodysplasia Ossificans Progressiva (FOP)

An International Cross-sectional Survey to Evaluate the Burden of Fibrodysplasia Ossificans Progressiva (FOP) on Patients and Their Families.

NCT04665323

Fibrodysplasia Ossificans Progressiva

TERMINATEDPhase 2

In-Home Evaluation of Episodic Administration of Palovarotene in Fibrodysplasia Ossificans Progressiva (FOP) Subjects

NCT02521792

Fibrodysplasia Ossificans Progressiva

View all related studies

Sponsors

Lead Sponsor

Daiichi Sankyo Co., Ltd.

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 3, 2022Data synced to Clareo: April 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions